At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Clobetasol + Spironolactone +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy
In Brief
A Phase 2 clinical trial evaluating Clobetasol + Spironolactone, Clobetasol + Placebo, and 2 other interventions for Cutaneous Atrophy Due to Corticosteroids. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether spironolactone could significantly reduce cutaneous atrophy due to corticosteroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Atrophy Due to Corticosteroids
CountriesFrance
CollaboratorsSociété de Dermatologie Française
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartSep 2011
Primary CompletionMay 2012
TodayJul 2026
First PostedAug 2, 2011
Enrollment StartSep 1, 2011
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.9 years ago
Interventions
Clobetasol + Spironolactonedrug
One application 6 days a week during 4 weeks
Clobetasol + Placebodrug
One application 6 days a week during 4 weeks
Placebo + Spironolactonedrug
One application 6 days a week during 7 weeks
Placebo + Placebodrug
One application 6 days a week during 7 weeks